U.S. Sex Reassignment Hormone Therapy Market Size & Share 2026-2035

U.S. Sex Reassignment Hormone Therapy Market Size

The U.S. sex reassignment hormone therapy market size was valued at USD 1.8 billion in 2025. The market is expected to grow from USD 1.9 billion in 2026 to USD 3.1 billion in 2035, at a CAGR of 5.8% during the forecast period, according to the latest report published by Global Market Insights Inc.

Increasing awareness and acceptance about sex reassignment treatments, expansion of specialized gender clinics, surge in number of gender-affirming surgeries, and rise in availability of novel hormonal therapies with better efficacy, among other factors, are driving the market growth. Rising insurance coverage for hormone therapy and increasing research on gender dysphoria treatment outcomes are expected to propel the industry demand. AbbVie Inc., Pfizer, ASCEND THERAPEUTICS, Mallinckrodt Pharmaceuticals, and Noven are among the leading players operating in the market. These players mainly focus on product innovation, geographic expansion, and collaboration with local healthcare providers, among others.
 

The market has increased from USD 1.6 billion in 2022 and reached USD 1.7 billion in 2024, with the historic growth rate of 4.4%. As the social acceptance of both gender identities increases, there is a growing number of individuals accessing hormone therapy and other gender-affirming medical services. Increased public education and representation in the media, as well as advocacy efforts, have reduced stigma and allowed more patients to seek care with more confidence. As a result, healthcare institutions and professional organizations have increased access through a greater emphasis on inclusivity and competent care for transgender patients. Consequently, health insurance providers and employers have expanded coverage, which also helped in reducing financial barriers to care. As the number of individuals who feel safe disclosing their gender dysphoria and seeking care increases, the demand for hormone therapy continues to rise, substantially driving overall market growth.
 

Additionally, with the improvement of hormone drugs such as long-acting injectables, transdermal systems, and bio-identical hormones, hormone therapy has become more effective, safe, and convenient for patients. In addition to reducing side effects and providing more stable hormone levels, these new products also offer personalized treatment methods that improve patient satisfaction and long-term compliance. All of these advances have given clinicians greater confidence in prescribing newer options because they have clinical research supporting clinical dosing procedures and monitoring tools. Pharmaceutical manufacturers are also focusing on better delivery methods and implementing more sustained-release technologies to provide patients with a greater variety of applications when receiving hormone therapy. All of these advancements have made hormone therapy more encouraging and accessible for patients and are helping to drive the growth of the U.S. sex reassignment hormone therapy market.
 

Further, the rise in the number of people opting for gender-affirming surgeries, such as breast augmentation, chest reconstruction, facial feminization, and genital reconstruction is a major driver for increasing hormone therapy requirements. The patients may need hormones to prepare for the surgery, during their recovery period (after the surgery), and to receive the best possible surgical outcome. As more surgical centers and surgeons specialize in gender‑affirming procedures, a larger patient population simultaneously enters the hormone‑therapy pathway. Furthermore, as insurance coverage for these surgeries improves, more individuals may opt for undergoing full transition procedures. Thus, the resulting interconnected growth of the number of surgeries is anticipated to fuel the industry growth over the forecast timeframe.
 

Sex reassignment hormone therapy refers to the medical process of administering hormones, such as estrogen for transgender women or testosterone for transgender men, to help align an individual's physical characteristics with their gender identity. This therapy is a key component of gender-affirming care, aiding in the development of secondary sexual characteristics that match a person's identified gender.

U.S. Sex Reassignment Hormone Therapy Market Trends

Expansion of telehealth-based hormone therapy, increasing social acceptance and awareness, advancements in hormone formulations, and expansion of specialized gender clinics are among the key trends shaping the market growth positively.
 

• Telemedicine platforms are making hormone therapy more accessible, especially for individuals in rural or underserved areas. The new way of accessing care through virtual consultations, digital prescriptions, and remote monitoring reduces the time needed to access care as well as removes geographical barriers to accessing care, resulting in significantly greater utilization of care and facilitating broader uptake of therapy among the various populations eligible to receive treatment.
   
• Additionally, the development of new ways to deliver hormones (including long-acting injectables, transdermal patches, and bioidentical hormone products) has improved patient safety, convenience, and consistency of use. In addition, these new products may reduce the incidence of side effects experienced by patients and improve the rate of patients' adherence to treatment protocols, making hormone therapy more attractive to potential users. All these parameters are expected to propel the market toward more widespread acceptance and continued growth.
   
• Further, more extensive social acknowledgment of transgender and nonbinary identity will promote greater numbers of people accessing medical transition services. Increased awareness, supportive policy, and inclusive healthcare training may help to reduce stigma, improve provider competence, increase patient engagement, and grow the pool of hormone therapy users.
   

U.S. Sex Reassignment Hormone Therapy Market Analysis

Based on gender transition, the U.S. sex reassignment hormone therapy market is segmented into male-to-female (MTF) and female-to-male (FTM). The male-to-female (MTF) segment accounted for a leading share of 55.7% in 2025. Improved clinical guidelines for hormone‑replacement therapies is a key factor fueling the segmental growth. The segment is expected to reach USD 1.7 billion by 2035, growing at a CAGR of 5.6% during the forecast period.
 

• Hormone therapy for male to female (MTF) is an approach for developing female secondary sexual characteristics using both estrogen and androgen-blocking medications. The growing social acceptance of transgender persons, as well as the rise in number of clinicians with expertise in transgender health care, has increased the number of transgender women who are seeking medical care.
   
• Estrogen replacement therapy provides breast growth, redistribution of body fat and softens skin, whereas anti-androgens suppress masculine traits.
   
• Additionally, demand is rising as more individuals undergo early transition, supported by improved insurance coverage and telehealth platforms. The MTF category is experiencing strong market growth because of the continuous need for hormone replacement as well as the growing public awareness of safe, medically supervised pathways to transition.
   
• The female-to-male (FTM) segment was valued at USD 791.8 million in 2025. The female-to-male (FTM) segment of the population who use hormone therapy usually receive testosterone injections for creating male-like physical characteristics (e.g., deepening voice, long growth of body hair, development of muscle mass, and stopping menstrual cycles).
   
• Further, the increase in number of people diagnosed with gender identity disorder combined with wider availability of testosterone in multiple formulations (including injectables, gels, and patches), has resulted in number of people receiving hormone injections.
   
• Many FTM individuals undergo long‑term hormone therapy, making this segment a stable revenue contributor. Moreover, increased access to care via community clinics, telehealth, and supportive public policies have contributed to surge in the number of people using hormone injections to transition.
   
• Furthermore, the growth of acceptance of being transgender and standardization of the delivery of health care has created a steady increase in the target population who wish to transition from female-to-male.
   

Based on type, the U.S. sex reassignment hormone therapy market is segmented into estrogen, testosterone and puberty blockers. The estrogen segment accounted for the leading market share of 45% in 2025.
 

• Estrogen replacement therapy plays an important role in MTF transitioning by facilitating the process of feminization through physical changes (such as breast development and redistribution of body fat).
   
• Additionally, the development of safer delivery systems for estrogen products, including patches, injections, and bioidentical products, has resulted in improved adherence to regimens and expanded the use of estrogen products among those seeking gender‑affirming care.
   
• In addition, since estrogen is a key component of the long-term maintenance of an individual's transition, estrogen is one of the most commonly prescribed drugs for gender-affirming care.
   
• Further, increased training of clinicians and greater confidence among patients in their ability to undergo medical transition are resulting in more people requesting estrogen therapies.
   
• FTM people primarily use testosterone to facilitate masculine attributes such as voice deepening, enhancing facial and body hair, and building muscle. Availability of multiple dose options provides flexibility for patients, encouraging ongoing use of treatment.
   
• Furthermore, increased accessibility through primary care practitioners, via telehealth appointment systems, and through community health providers has boosted access to therapy significantly. The continuing need for lifelong therapies for the majority of FTM patients may provide ongoing market stability, as the vast majority will utilize testosterone therapy throughout their adult lives.
   
• The puberty blockers segment was valued at USD 319.9 million in 2025. Gender dysphoria often occurs during puberty, and puberty blockers are prescribed to help temporarily stop an individual from experiencing unwanted changes. This allows young people the opportunity to explore their gender identity before making any permanent physical changes.
   
• Moreover, the adoption of puberty blockers is also rising within the healthcare system due to increased awareness among parents, providers, and educators regarding the psychological benefits of early intervention.
   

Based on distribution channel, the U.S. sex reassignment hormone therapy market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment accounted for the leading market share of 40.7% in 2025.
 

• Patients receiving gender-affirming care can obtain their treatment through an integrated clinical system in hospital pharmacies. They play a crucial role in prescribing and dispensing medications used for patients who are transitioning or have complex care needs.
   
• Additionally, these pharmacies provide direct supervision, work in conjunction with endocrinologists for care coordination, and implement structured monitoring protocols. As there is growing demand for this channel due to the increasing number of hospitals and academic institutions that are developing gender-affirming programs, the hospital pharmacy continues to play an important role in managing injectable and specialty formulations that require a medical professional's supervision.
   
• As hospitals increasingly adopt inclusive care models for their patients, the role of the hospital pharmacy related to dispensing hormone therapy has increased as well.
• Retail pharmacies continue to be one of the main points of access for both new and continuing patients. With the availability of oral, injectable, and transdermal formulations in retail chain locations, pharmacies are a convenient option for routine refilling and managing ongoing therapy.
   
• Further, extended hours and integration with insurance also support high reliability and access. As gender-affirming treatment is becoming a regular part of community-based healthcare, retail pharmacies also play an increasingly important role in the continued growth of the gender-affirming treatment market.
   
• The online pharmacies segment is anticipated to grow with the fastest CAGR of 6.4% over the forecast period. The availability of online pharmacies has greatly improved the accessibility of hormone therapies, as ordering can be done discreetly and conveniently from home.
   
• Furthermore, many online pharmacies use integrated digital platforms to connect users with telehealth providers, which allows for a more efficient process of prescribing and following up.
   
• In addition, the use of automated refills and flexible delivery options helps to increase adherence to hormone therapy.
   

East South Central Sex Reassignment Hormone Therapy Market

The East South Central sex reassignment hormone therapy market was valued at USD 397.6 million and USD 417.4 million in 2022 and 2023, respectively. In 2025 the market size was valued at USD 460.9 million from USD 438.4 million in 2024.
 

• The East South Central region is experiencing steady growth in gender‑affirming hormone therapy as healthcare systems expand inclusivity initiatives and more primary care practitioners receive training in transgender health. In addition, the region has seen increasing visibility of LGBTQ+ communities, which encourages more individuals to seek medically guided transitions.
   
• Urban areas such as Nashville, Louisville, and Birmingham are becoming hubs for specialized clinics and telehealth‑supported care, reducing dependence on distant metropolitan centers.
   
• Further, insurance expansion through employer‑sponsored plans and Medicaid programs in select states has improved affordability, contributing to market growth.
   

West South Central Sex Reassignment Hormone Therapy Market

West South Central accounted for a significant share of the U.S. sex reassignment hormone therapy market and was valued at USD 355.9 million in 2025.
 

• Growth in the West South Central region is shaped by a combination of strong medical infrastructure in major cities and a rising willingness among patients to pursue gender‑affirming care.
   
• Additionally, telehealth has played a critical role in maintaining access, especially where local healthcare environments are restrictive. Many individuals rely on online pharmacies and virtual providers to obtain hormone therapy discreetly and consistently.
   
• Moreover, expanding private‑sector insurance coverage and increased mental‑health screening for gender dysphoria have also contributed to sustained demand. The region overall shows resilient growth, supported by digital healthcare innovation and diverse patient pathways.
   

South Atlantic Sex Reassignment Hormone Therapy Market

The South Atlantic sex reassignment hormone therapy market accounted for a substantial share of the market and was valued at USD 288.1 million in 2025.
 

• The South Atlantic region is among the fastest‑growing zones for gender‑affirming hormone therapy, driven by large urban centers, diverse populations, and expanding acceptance of transgender healthcare needs.
   
• States such as Florida, Georgia, and North Carolina have seen a rise in specialized clinics, while metropolitan hubs like Atlanta, Miami, Charlotte, and Washington, D.C., offer comprehensive transition‑care networks.
   
• In addition, insurance reforms and employer‑based coverage in corporate‑dense cities contribute to improved affordability. Although certain states in the region face policy fluctuations, the overall environment remains supportive for adults seeking hormone therapy.
   

U.S. Sex Reassignment Hormone Therapy Market Share

The competitive landscape of the U.S. sex reassignment hormone therapy market is shaped by a mix of large pharmaceutical manufacturers, specialty hormone therapy providers, compounding pharmacies, and emerging telehealth platforms. Major pharmaceutical companies play a critical role by producing key hormonal agents such as estradiol, testosterone, anti‑androgens, and puberty‑blocking medications. Their advantage lies in established distribution networks, regulatory experience, and the ability to scale production to meet rising demand.
 

Additionally, specialty pharmaceutical firms focus on advanced formulations such as long‑acting injectables, bioidentical hormones, and improved transdermal delivery systems, which differentiate them through safety, convenience, and better patient adherence.
 

Telehealth companies represent one of the fastest‑growing competitive segments, providing virtual consultations, digital prescription management, and home‑delivery services. Their convenience, privacy, and nationwide reach make them particularly appealing for patients in restrictive or underserved regions.
 

Overall, competition is intensifying as awareness increases, clinical guidelines evolve, and more companies seek to meet the expanding demand for gender‑affirming medications. Innovation in drug delivery, affordability strategies, and patient‑centric care models continues to shape the competitive dynamics of the market.
 

U.S. Sex Reassignment Hormone Therapy Market Companies

A few of the prominent players operating in the U.S. sex reassignment hormone therapy industry include:

• AbbVie Inc.
• ASCEND THERAPEUTICS
• Azurity Pharmaceuticals, Inc.
• BIOTE MEDICAL
• Eli Lilly and Company
• Halozyme Therapeutics
• Mallinckrodt Pharmaceuticals
• Noven
• Pfizer
• Teva Pharmaceuticals
   
• AbbVie Inc.

AbbVie focuses on expanding hormone‑therapy offerings through advanced formulations, strengthening partnerships with healthcare providers, enhancing patient‑support programs, and investing in R&D to improve long‑term safety, efficacy, and accessibility across gender‑affirming care.
 

• Pfizer

Pfizer emphasizes innovation in hormone‑based therapies, ensuring stable supply of essential medications, expanding distribution channels, and leveraging large‑scale manufacturing capabilities to support wider national access for gender‑affirming hormone treatments.
 

The U.S. sex reassignment hormone therapy market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Gender Transition

• Male-To-Female (MTF)
• Female-To-Male (FTM)

Market, By Type

• Estrogen
• Testosterone
• Puberty blockers

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following zones:

• East South Central
• West South Central
• South Atlantic
• Mountain States
• East North Central
• Northeast
• Pacific Central
• West North Central